GT201400120A - Procedimiento de formulación de una vacuna que contiene al menos dos antígenos susceptibles de adsorberse en oxihidróxido de aluminio - Google Patents

Procedimiento de formulación de una vacuna que contiene al menos dos antígenos susceptibles de adsorberse en oxihidróxido de aluminio

Info

Publication number
GT201400120A
GT201400120A GT201400120A GT201400120A GT201400120A GT 201400120 A GT201400120 A GT 201400120A GT 201400120 A GT201400120 A GT 201400120A GT 201400120 A GT201400120 A GT 201400120A GT 201400120 A GT201400120 A GT 201400120A
Authority
GT
Guatemala
Prior art keywords
adsorberse
antigens
susceptible
formulation
procedure
Prior art date
Application number
GT201400120A
Other languages
English (en)
Inventor
Landry Bertaux
Isabelle Charconac
Alain Francon
Jean-Francois Hau
Sandrine Lentsch Graf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201400120A publication Critical patent/GT201400120A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE AL DOMINIO DE LAS COMBINACIONES DE VACUNAS QUE COMPRENDE A LA VEZ LA VALENCIA DE HEPATITIS B CONSTITUIDA POR EL ANTÍGENO DE SUPERFICIE DEL VIRUS DE HEPATITIS B (HBSAG) Y LA VALENCIA DE HAEMOPHILUS INFLUENZAE TIPO B, CONSTITUIDA POR SU POLISACÁRIDO CAPSULAR, LLAMADO POLIRRIBOSILRIBITOLFOSFATO (PRP) QUE, PARA SER EFICAZ EN NIÑOS MENORES DE DOS AÑOS, SE CONJUGA EN UNA PROTEÍNA PORTADORA, POR EJEMPLO LA PROTEÍNA TETÁNICA
GT201400120A 2012-01-17 2014-06-19 Procedimiento de formulación de una vacuna que contiene al menos dos antígenos susceptibles de adsorberse en oxihidróxido de aluminio GT201400120A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1250464A FR2985663B1 (fr) 2012-01-17 2012-01-17 Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium

Publications (1)

Publication Number Publication Date
GT201400120A true GT201400120A (es) 2015-09-17

Family

ID=47714410

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400120A GT201400120A (es) 2012-01-17 2014-06-19 Procedimiento de formulación de una vacuna que contiene al menos dos antígenos susceptibles de adsorberse en oxihidróxido de aluminio

Country Status (34)

Country Link
US (1) US9358294B2 (es)
EP (1) EP2804628B1 (es)
JP (2) JP6199310B2 (es)
KR (1) KR102019848B1 (es)
CN (1) CN104039348B (es)
AP (1) AP2014007848A0 (es)
AR (1) AR089737A1 (es)
AU (1) AU2013210927B2 (es)
BR (1) BR112014017416B1 (es)
CA (1) CA2861304C (es)
CR (1) CR20140356A (es)
CY (1) CY1119206T1 (es)
DK (1) DK2804628T3 (es)
EA (1) EA026058B1 (es)
ES (1) ES2625011T3 (es)
FR (1) FR2985663B1 (es)
GE (1) GEP201706642B (es)
GT (1) GT201400120A (es)
HK (1) HK1204293A1 (es)
HR (1) HRP20170692T1 (es)
HU (1) HUE032539T2 (es)
IL (1) IL233643A (es)
LT (1) LT2804628T (es)
MX (1) MX349411B (es)
NZ (1) NZ627345A (es)
PE (1) PE20141515A1 (es)
PH (1) PH12014501546B1 (es)
PL (1) PL2804628T3 (es)
PT (1) PT2804628T (es)
RS (1) RS55962B1 (es)
SI (1) SI2804628T1 (es)
UA (1) UA113000C2 (es)
WO (1) WO2013107988A1 (es)
ZA (1) ZA201405431B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106075428A (zh) * 2015-07-01 2016-11-09 北京科兴中维生物技术有限公司 一种免疫原性组合物及其制备方法
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
WO2022224966A1 (ja) 2021-04-20 2022-10-27 Ｋｍバイオロジクス株式会社 ６種混合液状ワクチン組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3626996B2 (ja) * 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
US6790445B1 (en) * 1997-02-06 2004-09-14 Merck & Co., Inc. Preservatives for vaccines
DE69841708D1 (de) * 1997-02-06 2010-07-22 Merck Sharp & Dohme Thimerosal-freie konservierungsmittel für impfstoffe
EP1028750B1 (en) * 1997-09-15 2006-02-01 Sanofi Pasteur MSD Method for preparing multivalent vaccines
AU2002330681C1 (en) * 2001-07-26 2015-04-02 Glaxosmithkline Biologicals S.A. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003013500A1 (en) 2001-08-07 2003-02-20 Laboratoires Smb Sa Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it
FR2828406B1 (fr) * 2001-08-08 2005-06-24 Aventis Pasteur Composition vaccinale bivalente havi
GB0610140D0 (en) * 2006-05-22 2006-06-28 Insense Ltd Protein stability
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion

Also Published As

Publication number Publication date
IL233643A (en) 2017-04-30
PH12014501546A1 (en) 2014-10-08
HK1204293A1 (en) 2015-11-13
BR112014017416A8 (pt) 2017-07-04
KR102019848B1 (ko) 2019-09-09
JP6199310B2 (ja) 2017-09-20
LT2804628T (lt) 2017-05-25
AP2014007848A0 (en) 2014-08-31
FR2985663A1 (fr) 2013-07-19
JP2015504085A (ja) 2015-02-05
UA113000C2 (uk) 2016-11-25
US20140370049A1 (en) 2014-12-18
RS55962B1 (sr) 2017-09-29
DK2804628T3 (en) 2017-05-22
US9358294B2 (en) 2016-06-07
HUE032539T2 (hu) 2017-10-30
AU2013210927A1 (en) 2014-08-28
CN104039348B (zh) 2016-05-11
KR20140119109A (ko) 2014-10-08
NZ627345A (en) 2016-07-29
CA2861304C (fr) 2021-05-25
GEP201706642B (en) 2017-03-27
CA2861304A1 (fr) 2013-07-25
BR112014017416B1 (pt) 2022-08-16
EA201491387A1 (ru) 2014-12-30
BR112014017416A2 (pt) 2021-05-25
WO2013107988A1 (fr) 2013-07-25
CR20140356A (es) 2014-08-28
CY1119206T1 (el) 2018-02-14
JP6356886B2 (ja) 2018-07-11
HRP20170692T1 (hr) 2017-07-14
ES2625011T3 (es) 2017-07-18
FR2985663B1 (fr) 2015-03-27
PT2804628T (pt) 2017-04-21
EA026058B1 (ru) 2017-02-28
PL2804628T3 (pl) 2017-08-31
MX2014007850A (es) 2014-08-21
MX349411B (es) 2017-07-27
ZA201405431B (en) 2015-12-23
PE20141515A1 (es) 2014-11-04
PH12014501546B1 (en) 2014-10-08
AR089737A1 (es) 2014-09-10
CN104039348A (zh) 2014-09-10
EP2804628B1 (fr) 2017-03-01
AU2013210927B2 (en) 2017-02-23
JP2017203043A (ja) 2017-11-16
IL233643A0 (en) 2014-08-31
SI2804628T1 (sl) 2017-06-30
EP2804628A1 (fr) 2014-11-26

Similar Documents

Publication Publication Date Title
CO2017004119A2 (es) Partículas tipo virus modificadas de cmv
MX2018007627A (es) Vacuna contra el virus del zika.
CL2016000358A1 (es) Vacuna para adenovirus aviar
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
ECSP14013201A (es) Formulaciones parenterales de vacunas contra los norovirus
PE20160686A1 (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
CO6970603A2 (es) Composiciones y métodos para tratar el virus de la hepatitis c
GT201500005A (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
EA201691348A1 (ru) Однофлаконные вакцинные составы
AR101455A1 (es) Molécula portadora
HK1222569A1 (zh) 用於誘導免疫反應的糖疫苗組合物及其治療癌症的用途
BRPI0923448A2 (pt) vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina.
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
GB201303406D0 (en) Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition
BR112015008417A2 (pt) composição imunogênica, e, vacina
BR112014009887A2 (pt) vacinmas e métodos para desenvolvimento de vacina para indução de imunidade a todos os sorotipos de virus da dengue
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
DK3244920T3 (da) Mund- og klovsyge-vaccine
GT201400120A (es) Procedimiento de formulación de una vacuna que contiene al menos dos antígenos susceptibles de adsorberse en oxihidróxido de aluminio
CL2015001659A1 (es) Composición inmunogénica que comprende antígenos de mycoplasma
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
BR112015002979B8 (pt) Forma cristalina, e, composição farmacêutica
GT201300316A (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano
BR112014023283A8 (pt) Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza